•Immune checkpoint inhibitors can be safely administered to patients with dermatomyositis.•Immunosuppressants did not impact the efficacy of treatment with an immune check point inhibitor.•Patients with autoimmune disorders who require immune check point inhibitors should be monitored by a rheumatologist.
Keywords: Dermatomyositis; MMR deficiency; Microsatellite instability; Ovarian cancer; Pembrolizumab.
© 2022 The Authors. Published by Elsevier Inc.